Actively Recruiting

Phase 3
Age: 50Years - 85Years
All Genders
NCT07262645

Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)

Led by Danyang Huichuang Medical Equipment Co., Ltd. · Updated on 2025-12-03

320

Participants Needed

23

Research Sites

83 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is a multicenter, randomized, double-blind, placebo (sham device)-controlled clinical trial. A total of 320 patients with mild to moderate Alzheimer's disease (AD) are planned to be enrolled. Central stratified block randomization will be applied, with stratification based on disease severity (mild vs. moderate) and PET subgroup participation status (yes vs. no). Participants will be randomly assigned to either the treatment group or control group in a 1:1 ratio. After enrollment, participants will complete the treatment at home. The treatment group will receive therapy using a near-infrared light therapy device, while the control group will use sham device. Both investigators and participants will remain blinded to treatment allocation throughout the study.

CONDITIONS

Official Title

Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)

Who Can Participate

Age: 50Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female participants aged between 50 to 85 years old (inclusive).
  • At least 4 years of formal education and able to complete cognitive and other assessments.
  • Documented progressive memory decline for 12 months or more before screening.
  • Meet core clinical diagnostic criteria for mild to moderate Alzheimer's disease dementia (stages 4-5) per NIA-AA 2018 and AA 2024 update.
  • Evidence of positive brain amyloid pathology by positive Ab2-PET scan or cerebrospinal fluid Ab2 test.
  • Mini-Mental State Examination score between 15 and 26 inclusive (or 12 to 22 if elementary school education).
  • Clinical Dementia Rating Global score of 1 or 2, with Memory Box score e 0.5.
  • Stable dose of acetylcholinesterase inhibitor or memantine for at least 12 weeks if currently treated.
  • Have a reliable study partner who can support daily treatment and communicate with study staff.
  • Provide written informed consent voluntarily before any study procedures.
Not Eligible

You will not qualify if you...

  • Diagnosis other than Alzheimer's disease that may cause dementia or cognitive decline (e.g., vascular dementia, CNS infections, Creutzfeldt-Jakob disease, Huntington's disease, Parkinson's disease, Lewy body dementia, traumatic brain injury-related dementia, or dementia due to physical or chemical factors).
  • Brain MRI showing significant abnormalities such as multiple large infarcts, extensive white matter changes, or space-occupying lesions (except small meningiomas or arachnoid cysts under 1 cm).
  • History of transient ischemic attack, stroke, or seizure within 6 months prior to screening.
  • Hachinski Ischemic Score greater than 4.
  • Hamilton Depression Rating Scale score greater than 10.
  • Diagnosis of psychiatric disorders including schizophrenia, bipolar disorder, major depression, or delirium.
  • Known HIV infection or neurosyphilis.
  • Severe cardiovascular disease or recent unstable angina or myocardial infarction.
  • Severe dysfunction of major organs or any condition making participation unsafe.
  • Prior or current treatment with anti-amyloid monoclonal antibodies.
  • Prior or planned lymphaticovenous anastomosis of cervical deep lymphatic vessels.
  • Participation in other interventional trials within 30 days before screening.
  • History of severe head trauma or implanted cranial devices or contraindications to MRI.
  • Contraindications or allergy to PET tracer or FDG tracer for PET substudy.
  • History of malignancy within 5 years (with some exceptions for adequately treated cancers).
  • Women who are pregnant, breastfeeding, planning pregnancy, or not using effective contraception.
  • Any other condition deemed by the investigator to interfere with safety or study compliance.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 23 locations

1

Peking University First Hospital

Beijing, Beijing Municipality, China, 100032

Actively Recruiting

2

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China, 100050

Actively Recruiting

3

Xuanwu Hospital, Capital Medical University

Beijing, Beijing Municipality, China, 100053

Actively Recruiting

4

Peking University Third Hospital

Beijing, Beijing Municipality, China, 100191

Actively Recruiting

5

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China, 100730

Actively Recruiting

6

Shijiazhuang People's Hospital

Shijiazhuang, Hebei, China, 050000

Actively Recruiting

7

Baotou Central Hospital

Baotou, Inner Mongolia, China, 014040

Actively Recruiting

8

The Second Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China, 215004

Actively Recruiting

9

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China, 215006

Actively Recruiting

10

Tangdu Hospital, Air Force Medical University

Xi'an, Shaanxi, China, 710038

Actively Recruiting

11

The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China, 710061

Actively Recruiting

12

Shaanxi Provincial People's Hospital

Xi'an, Shaanxi, China, 710068

Actively Recruiting

13

Shanghai Mental Health Center

Shanghai, Shanghai Municipality, China, 200030

Actively Recruiting

14

Huashan Hospital, Fudan University

Shanghai, Shanghai Municipality, China, 200040

Actively Recruiting

15

Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China, 200127

Actively Recruiting

16

Pudong Hospital, Fudan University

Shanghai, Shanghai Municipality, China, 201399

Actively Recruiting

17

Shanxi Bethune Hospital

Taiyuan, Shanxi, China, 030001

Actively Recruiting

18

The First Hospital of Shanxi Medical University

Taiyuan, Shanxi, China, 030001

Actively Recruiting

19

General Hospital, Tianjin Medical University

Tianjin, Tianjin Municipality, China, 300052

Actively Recruiting

20

Tianjin Huanhu Hospital

Tianjin, Tianjin Municipality, China, 300060

Actively Recruiting

21

Tianjin People's Hospital

Tianjin, Tianjin Municipality, China, 300121

Actively Recruiting

22

The Second Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310009

Actively Recruiting

23

Affiliated Hospital of Hangzhou Normal University

Hangzhou, Zhejiang, China, 310015

Actively Recruiting

Loading map...

Research Team

Y

Yi Tang, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here